Cellectis SA

ALCLS

Company Profile

  • Business description

    Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

  • Contact

    8, rue de la Croix Jarry
    Paris75013
    FRA

    T: +33 181691600

    https://www.cellectis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    222

Stocks News & Analysis

stocks

After Earnings, is Alphabet stock a buy, a sell, or fairly valued?

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks

Moated ASX share crashes amid weak trading update

Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,015.4048.700.54%
CAC 407,862.365.000.06%
DAX 4024,156.0061.37-0.25%
Dow JONES (US)44,632.99204.57-0.46%
FTSE 1009,091.9144.41-0.49%
HKSE25,229.09295.36-1.16%
NASDAQ21,098.2980.29-0.38%
Nikkei 22540,654.7019.85-0.05%
NZX 50 Index12,855.9780.44-0.62%
S&P 5006,370.8618.91-0.30%
S&P/ASX 2008,756.4051.800.60%
SSE Composite Index3,615.726.010.17%

Market Movers